Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX^® mesalamine

References

• LoftusCGLoftusEVJrHarmsenWSUpdate on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000Inflamm Bowel Dis200713325426117206702
   PubMed Web of Science ®Google Scholar
• DaneseSFiocchiCUlcerative colitisN Engl J Med2011365181713172522047562
   PubMed Web of Science ®Google Scholar
• KornbluthASacharDBUlcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters CommitteeAm J Gastroenterol2010105350152320068560
   PubMed Web of Science ®Google Scholar
• RicartEPanaccioneRLoftusEVJrAutoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case–control studyInflamm Bowel Dis200410320721415290913
   PubMed Web of Science ®Google Scholar
• EkbomAHelmickCZackMAdamiHOUlcerative colitis and colorectal cancerN Engl J Med199032318122812332215606
   PubMed Web of Science ®Google Scholar
• EadenJAbramsKMayberryJThe risk of colorectal cancer in ulcerative colitis: a meta-analysisGut200148452653511247898
   PubMed Web of Science ®Google Scholar
• RothMPetersenGMcElreeCFeldmanERotterJGeographic origins of Jewish patients with inflammatory bowel diseaseGastroenterology19899749009042777043
   PubMed Web of Science ®Google Scholar
• LoftusEVClinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influencesGastroenterology200412661504151715168363
   PubMed Web of Science ®Google Scholar
• KappelmanMDRifas-ShimanSLKleinmanKThe prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United StatesClin Gastroenterol Hepatol20075121424142917904915
   PubMed Web of Science ®Google Scholar
• CosnesJGower–RousseauCSeksikPCortotAepidemiology and natural history of inflammatory bowel diseasesGastroenterology2011140617851794e178421530745
   PubMed Web of Science ®Google Scholar
• HalfvarsonJBodinLTyskCLindbergEJärnerotGInflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristicsGastroenterology200312471767177312806610
   PubMed Web of Science ®Google Scholar
• BurgerDTravisSConventional medical management of inflammatory bowel diseaseGastroenterology201114061827183721530749
   PubMed Web of Science ®Google Scholar
• CohenRDWosethDMThistedRAHanauerSBA meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitisAm J Gastroenterol20009551263127610811338
   PubMed Web of Science ®Google Scholar
• HarrisMLichtensteinGDelivery and efficacy of topical 5-aminosalicylic acid (mesalamine) therapy in the treatment of ulcerative colitisAliment Pharmacol Ther2011339996100921385194
   PubMed Web of Science ®Google Scholar
• MarshallJIrvineERectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysisAliment Pharmacol Ther1995932933007654892
   PubMed Web of Science ®Google Scholar
• FordACKhanKJAchkarJ-PMoayyediPEfficacy of oral vs topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysisAm J Gastroenterol2012107216717622108446
   PubMed Web of Science ®Google Scholar
• FordACKhanKJSandbornWJHanauerSBMoayyediPEfficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysisClin Gastroenterol Hepatol201210551351922083024
   PubMed Web of Science ®Google Scholar
• SutherlandLMacdonaldJOral 5-aminosalicylic acid for induction of remission in ulcerative colitisCochrane Database Syst Rev20062CD00054316625536
   PubMedGoogle Scholar
• SutherlandLRothDBeckPMayGMakiyamaKOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisCochrane Database Syst Rev20062CD00054416625537
   PubMedGoogle Scholar
• FordACAchkarJPKhanKJEfficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysisAm J Gastroenterol2011106460161621407188
   PubMed Web of Science ®Google Scholar
• ItoHIidaMMatsumotoTDirect comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized studyInflamm Bowel Dis20101691567157420049950
   PubMed Web of Science ®Google Scholar
• FordACKhanKJSandbornWJKaneSVMoayyediPOnce-daily dosing vs conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysisAm J Gastroenterol2011106122070207721894226
   PubMed Web of Science ®Google Scholar
• BernardFHerveHGilbertTOnce-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded studyGastroenterology20121425 Suppl 1S-197
   Web of Science ®Google Scholar
• PierikMJFlourieBHagegeHOnce-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: mucosal healing and early response data from motus, a multicentre, controlled, randomised, investigator-blinded studyGastroenterology20121425 Suppl 1S-198
   Web of Science ®Google Scholar
• PranteraCKohnACampieriMClinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX® with Asacol®Aliment Pharmacol Ther200930990891819678813
   PubMed Web of Science ®Google Scholar
• KaneSKatzSJamalMMStrategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitisInflamm Bowel Dis20121861026103321837775
   PubMed Web of Science ®Google Scholar
• OrchardTRvan der GeestSAPTravisSPLRandomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis – new light on a familiar questionAliment Pharmacol Ther20113391028103521385195
   PubMed Web of Science ®Google Scholar
• LichtensteinGRRutgeertsPImportance of mucosal healing in ulcerative colitisInflamm Bowel Dis201016233834619637362
   PubMed Web of Science ®Google Scholar
• LichtensteinGRamseyDRubinDRandomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs 2.4 g/day in endoscopic mucosal healing–ASCEND I and II combined analysisAliment Pharmacol Ther201133667267821255059
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSLichtensteinGRSafdiMEdelineMScott HarrisMEarly symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis – additional results from two controlled studiesAliment Pharmacol Ther201134774775621848857
   PubMed Web of Science ®Google Scholar
• LichtensteinGRAbreuMTCohenRTremaineWAmerican Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel diseaseGastroenterology2006130394098716530532
   PubMed Web of Science ®Google Scholar
• CarbonnelFMethotrexate: a drug of the future in ulcerative colitis?Curr Drug Targets201112101413141621466494
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353232462247616339095
   PubMed Web of Science ®Google Scholar
• YamamotoTUmegaeSMatsumotoKMucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort studyInflamm Bowel Dis201016111905191120310015
   PubMed Web of Science ®Google Scholar
• MossACPeppercornMASteroid-refractory severe ulcerative colitis: what are the available treatment options?Drugs20086891157116718547130
   PubMed Web of Science ®Google Scholar
• MoscandrewMMahadevanUKaneSGeneral health maintenance in IBDInflamm Bowel Dis20091591399140919591135
   PubMed Web of Science ®Google Scholar
• FiorinoGFriesWDe La RueSMalesciARepiciADaneseSNew drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gutCurr Med Chem201017171851185720353384
   PubMed Web of Science ®Google Scholar
• Fernandez-BeckerNQMossACImproving delivery of aminosalicy-lates in ulcerative colitis: effect on patient outcomesDrugs20086881089110318484800
   PubMed Web of Science ®Google Scholar
• KammMASandbornWJGassullMOnce-daily, high- concentration MMX mesalamine in active ulcerative colitisGastroenterology20071321667517241860
   PubMed Web of Science ®Google Scholar
• HussainFAjjanRKapurKMoustafaMRileySOnce versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parametersAliment Pharmacol Ther2001151536211136278
   PubMed Web of Science ®Google Scholar
• De VosMVerdievelHSchoonjansRPraetMBogaertMBarbierFConcentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparationsGut19923310133813421446856
   PubMed Web of Science ®Google Scholar
• SandbornWHanauerSBuchAComparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteersAliment Pharmacol Ther200419101089109815142198
   PubMed Web of Science ®Google Scholar
• KlotzUClinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acidClin Pharmacokinet19851042853022864155
   PubMed Web of Science ®Google Scholar
• Shire US IncLialda (mesalamine) delayed release tablets: US prescribing information [online] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022000s003lbl.pdfAccessed March 23, 2012
   Google Scholar
• AkihoHIharaEMotomuraYNakamuraKCytokine-induced alterations of gastrointestinal motility in gastrointestinal disordersWorld J Gastrointest Pathophysiol201125728122013552
   PubMedGoogle Scholar
• SandbornWBalanGKuzmakBHanauerSComparable pharmacokinetics of two delayed release formulations of oral mesalamineAm J Gastroenterol2007102S465
   PubMed Web of Science ®Google Scholar
• SandbornWHanauerSThe pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitisAliment Pharmacol Ther2003171294212492730
   PubMed Web of Science ®Google Scholar
• DesreumauxPGhoshSReview article: mode of action and delivery of 5-aminosalicylic acid–new evidenceAliment Pharmacol Ther200624Suppl 12916939423
   PubMed Web of Science ®Google Scholar
• DubuquoyLRousseauxCThuruXPPAR-γ as a new therapeutic target in inflammatory bowel diseasesGut9120065591341134916905700
   PubMed Web of Science ®Google Scholar
• StensonWLobosESulfasalazine inhibits the synthesis of chemotactic lipids by neutrophilsJ Clin Invest19826924944976120182
   PubMed Web of Science ®Google Scholar
• MahidaYLammingCGallagherAHawthorneAHawkeyC5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel diseaseGut199132150541846838
   PubMed Web of Science ®Google Scholar
• KaiserGCYanFPolkDBMesalamine blocks tumor necrosis factor growth inhibition and nuclear factor [kappa] B activation in mouse colonocytesGastroenterology1999116360260910029619
   PubMed Web of Science ®Google Scholar
• EganLJMaysDCHuntoonCJInhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activityJ Biol Chem199927437264482645310473604
   PubMed Web of Science ®Google Scholar
• SandovalMLiuXMannickEClarkDMillerMPeroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamineGastroenterology19971135148014889352850
   PubMed Web of Science ®Google Scholar
• LichtensteinGRKammMABodduPEffect of once-or twice- daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitisClin Gastroenterol Hepatol2007519510217234558
   PubMed Web of Science ®Google Scholar
• LichtensteinGKammMSandbornWLyneAJosephRMMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulationsAliment Pharmacol Ther200827111094110218363894
   PubMed Web of Science ®Google Scholar
• SandbornWJKammMALichtensteinGRLyneAButlerTJosephREMMX Multi Matrix System® mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trialsAliment Pharmacol Ther200726220521517593066
   PubMed Web of Science ®Google Scholar
• KammMALichtensteinGRSandbornWJEffect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitisInflamm Bowel Dis20091511818671232
   PubMed Web of Science ®Google Scholar
• KammMALichtensteinGRSandbornWJRandomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitisGut200857789390218272546
   PubMed Web of Science ®Google Scholar
• D’HaensGSandbornWJBarrettKOnce-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitisAm J Gastroenterol582012 [Epub ahead of print.]
   Google Scholar
• MossAPeppercornMThe risks and the benefits of mesalazine as a treatment for ulcerative colitisExpert Opin Drug Saf2007629910717367256
   PubMed Web of Science ®Google Scholar
• GuptaMKPollackSHutchingsJJMesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussionWorld J Gastrointest Pharmacol Ther20101613213421577308
   PubMedGoogle Scholar
• RansfordRLangmanMSulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of MedicinesGut200251453653912235076
   PubMed Web of Science ®Google Scholar
• GisbertJPGonzález-LamaYMatéJ5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic reviewInflamm Bowel Dis200713562963817243140
   PubMed Web of Science ®Google Scholar
• PitchumoniCRubinADasKPancreatitis in inflammatory bowel diseasesJ Clin Gastroenterol201044424625320087199
   PubMed Web of Science ®Google Scholar
• LoftusEJrKaneSBjorkmanDShort-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitisAliment Pharmacol Ther200419217918914723609
   PubMed Web of Science ®Google Scholar
• WorldMJStevensPEAshtonMARainfordDJMesalazine-associated interstitial nephritisNephro Dial Transplant1996114614621
   Web of Science ®Google Scholar
• LowryPFranklinCWeaverALeucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazideGut200149565666411600468
   PubMed Web of Science ®Google Scholar
• MarinellaMMesalamine and warfarin therapy resulting in decreased warfarin effectAnn Pharmacother19983278418429681104
   PubMed Web of Science ®Google Scholar
• RahimiRNikfarSRezaieAAbdollahiMPregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysisReprod Toxicol200825227127518242053
   PubMed Web of Science ®Google Scholar
• JankeKHKlumpBGregorMMeisnerCHaeuserWDeterminants of life satisfaction in inflammatory bowel diseaseInflamm Bowel Dis200511327228615735434
   PubMed Web of Science ®Google Scholar
• HoivikMLMoumBSolbergICHealth-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN studyInflamm Bowel Dis9202011 [Epub ahead of print.]
   Google Scholar
• SolomonDYarlasAHodgkinsPKarlstadtRYenLKaneSThe impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patientsAliment Pharmacol Ther2012351213652036
   Web of Science ®Google Scholar
• KaneSVCohenRDAikensJEHanauerSBPrevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitisAm J Gastroenterol200196102929293311693328
   PubMed Web of Science ®Google Scholar
• MoshkovskaTStoneMClatworthyJAn investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurementsAliment Pharmacol Ther20093011–121118112719785623
   PubMed Web of Science ®Google Scholar
• van StaaTPCardTLoganRLeufkensH5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological studyGut200554111573157815994215
   PubMed Web of Science ®Google Scholar
• KaneSShayaFMedication non-adherence is associated with increased medical health care costsDig Dis Sci20085341020102417934828
   PubMed Web of Science ®Google Scholar
• HigginsPDRRubinDKaulbackKSchoenfieldPKaneSSystematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flaresAliment Pharmacol Ther200929324725718945258
   PubMed Web of Science ®Google Scholar
• BernickSJKaneSInsight into the widespread problem of nonadherence to therapy in ulcerative colitis patientsExpert Rev Clin Immunol20106467768220594140
   PubMed Web of Science ®Google Scholar
• MossACBKAhmedACheifetzASDevienJYenLFactors influencing adherence to mesalamine in patients with inflammatory bowel disease: a patient reported qualitative analysisAm J Gastroenterol2011106S2S442
   Web of Science ®Google Scholar
• SandbornWJKorzenikJLashnerBOnce-daily dosing of delayed-release oral mesalamine (400 mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitisGastroenterology201013841286129620064514
   PubMed Web of Science ®Google Scholar
• KaneSSumnerMSolomonDJenkinsMTwelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions databaseDig Dis Sci201156123463347021879279
   PubMed Web of Science ®Google Scholar
• American Hospital Formulary ServicePharmacologic-Therapeutic Classification2010 Available from: http://www.ashp.org/ahfsAccessed May 2012
   Google Scholar
• BreretonNBodgerKKammMAHodgkinsPYanSAkehurstRA cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspectiveJ Med Econ201013114816120141380
   PubMedGoogle Scholar
• JessTLoftusEVVelayosFSRisk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, MinnesotaGastroenterology200613041039104616618397
   PubMed Web of Science ®Google Scholar
• KatsanosKHTatsioniAPedersenNCancer in inflammatory bowel disease 15years after diagnosis in a population-based European collaborative follow-up studyJ Crohns Colitis20115543044221939917
   PubMed Web of Science ®Google Scholar
• JessTSimonsenJJørgensenKTPedersenBVNielsenNMFrischMDeclining risk of colorectal cancer in patients with inflammatory bowel disease over 30 yearsGastroenterology4192012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• JessTRungoeCPeyrin–BirouletLRisk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studiesClin Gastroenterol Hepatol201210663964522289873
   PubMed Web of Science ®Google Scholar
• TangJSharifOPaiCSilvermanALMesalamine protects against colorectal cancer in inflammatory bowel diseaseDig Dis Sci20105561696170319705280
   PubMed Web of Science ®Google Scholar
• PinczowskiDEkbomABaronJYuenJAdamiHRisk factors for colorectal cancer in patients with ulcerative colitis: a case-control studyGastroenterology199410711171207912678
   PubMed Web of Science ®Google Scholar
• BernsteinCNNugentZBlanchardJF5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based studyAm J Gastroenterol2011106473173621407180
   PubMed Web of Science ®Google Scholar
• TerdimanJPJohnsonLKKimYSChemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled studyDig Dis Sci200954112488249619757048
   PubMed Web of Science ®Google Scholar
• VelayosFSTerdimanJPWalshJMEffect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studiesAm J Gastroenterol200510061345135315929768
   PubMed Web of Science ®Google Scholar